Journal of B.U.ON. : official journal of the Balkan Union of Oncology · 2017
Evaluation of clinical characteristics linked with the survival of patients with advanced-stage ovarian malignancies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Popovic Miroslav, Terzic Milan, Dotlic Jelena, Ceric-Banicevic Arnela
Аннотация
PURPOSE: To evaluate the potential influence of clinical characteristics on survival of patients with advanced-stage of ovarian malignancies.
METHODS: The study included 163 women with FIGO stages 3 and 4 ovarian malignancies. Detailed history (family history of malignancies, age, menopausal status, body mass index (BMI), parity, comorbidities, symptoms/signs) was taken from all patients including tumor histopathological findings. Patients were postoperatively followed up to 5 years and adverse events were recorded. Univariate and multivariate survival analyses were applied.
RESULTS: Patient median survival was 22.77 months (range 1-91). Almost 74% of women survived in the first postoperative year, but only 12.9% had 5-year survival. In the postoperative period, each additional 6 months presented significant risk for unfavorable outcome. Women who were menopausal (p=0.033) and especially if older than 65 years (p=0.016) had worse prognosis. Patients with BMI ≤25 kg/m2 had significantly longer postoperative survival (p=0.005; obesity hazard ratio/HR=1.525). Women with other gynecological or chronic illnesses had a significantly shorter postoperative survival (p=0.038; hazard ratio/HR=1.450). There were no significant differences in postoperative survival regarding patients' parity, presence of symptoms or positive family history. Two significant models adjusted for FIGO stage (p=0.046) and histological tumor type (p=0.003) encompassing all assessed patient characteristics that could influence survival were obtained.
CONCLUSIONS: The most important clinical characteristics that can be predictors of survival of patients with advanced ovarian malignancies are comorbidities and being overweight.
METHODS: The study included 163 women with FIGO stages 3 and 4 ovarian malignancies. Detailed history (family history of malignancies, age, menopausal status, body mass index (BMI), parity, comorbidities, symptoms/signs) was taken from all patients including tumor histopathological findings. Patients were postoperatively followed up to 5 years and adverse events were recorded. Univariate and multivariate survival analyses were applied.
RESULTS: Patient median survival was 22.77 months (range 1-91). Almost 74% of women survived in the first postoperative year, but only 12.9% had 5-year survival. In the postoperative period, each additional 6 months presented significant risk for unfavorable outcome. Women who were menopausal (p=0.033) and especially if older than 65 years (p=0.016) had worse prognosis. Patients with BMI ≤25 kg/m2 had significantly longer postoperative survival (p=0.005; obesity hazard ratio/HR=1.525). Women with other gynecological or chronic illnesses had a significantly shorter postoperative survival (p=0.038; hazard ratio/HR=1.450). There were no significant differences in postoperative survival regarding patients' parity, presence of symptoms or positive family history. Two significant models adjusted for FIGO stage (p=0.046) and histological tumor type (p=0.003) encompassing all assessed patient characteristics that could influence survival were obtained.
CONCLUSIONS: The most important clinical characteristics that can be predictors of survival of patients with advanced ovarian malignancies are comorbidities and being overweight.